Broder Michael S, Quock Tiffany P, Chang Eunice, Reddy Sheila R, Agarwal-Hashmi Rajni, Arai Sally, Villa Kathleen F
President and CEO, Partnership for Health Analytic Research, Beverly Hills, CA.
Associate Director, Health Economics & Outcomes Research, Jazz Pharmaceuticals, Palo Alto, CA, during this study.
Am Health Drug Benefits. 2017 Oct;10(7):366-374.
Hematopoietic stem-cell transplantation (HSCT) requires highly specialized, resource-intensive care. Myeloablative conditioning regimens used before HSCT generally require inpatient stays and are more intensive than other preparative regimens, and may therefore be more costly.
To estimate the costs associated with inpatient HSCT according to the type of the conditioning regimen used and other potential contributors to the overall cost of the procedure.
We used data from the Truven Health MarketScan insurance claims database to analyze healthcare costs for pediatric (age <18 years) and adult (age ≥18 years) patients who had autologous or allogeneic inpatient HSCT between January 1, 2010, and September 23, 2013. We developed an algorithm to determine whether conditioning regimens were myeloablative or nonmyeloablative/reduced intensity.
We identified a sample of 1562 patients who had inpatient HSCT during the study period for whom the transplant type and the conditioning regimen were determinable: 398 patients had myeloablative allogeneic HSCT; 195 patients had nonmyeloablative/reduced-intensity allogeneic HSCT; and 969 patients had myeloablative autologous HSCT. The median total healthcare cost at 100 days was $289,283 for the myeloablative allogeneic regimen cohort compared with $253,467 for the nonmyeloablative/reduced-intensity allogeneic regimen cohort, and $140,792 for the myeloablative autologous regimen cohort. The mean hospital length of stay for the index (first claim of) HSCT was 35.6 days in the myeloablative allogeneic regimen cohort, 26.6 days in the nonmyeloablative/reduced-intensity allogeneic cohort, and 21.8 days in the myeloablative autologous regimen cohort.
Allogeneic HSCT was more expensive than autologous HSCT, regardless of the regimen used. Myeloablative conditioning regimens led to higher overall costs than nonmyeloablative/reduced-intensity regimens in the allogeneic HSCT cohort, indicating a greater cost burden associated with inpatient services for higher-intensity preparative conditioning regimens. Pediatric patients had higher costs than adult patients. Future research should involve validating the algorithm for identifying conditioning regimens using clinical data.
造血干细胞移植(HSCT)需要高度专业化、资源密集型的护理。HSCT前使用的清髓性预处理方案通常需要住院治疗,且比其他预处理方案更为强化,因此可能成本更高。
根据所使用的预处理方案类型以及该手术总体成本的其他潜在影响因素,估算住院HSCT的成本。
我们使用来自Truven Health MarketScan保险理赔数据库的数据,分析2010年1月1日至2013年9月23日期间接受自体或异体住院HSCT的儿科(年龄<18岁)和成人(年龄≥18岁)患者的医疗费用。我们开发了一种算法来确定预处理方案是清髓性还是非清髓性/降低强度的。
我们确定了研究期间1562例接受住院HSCT的患者样本,其移植类型和预处理方案是可确定的:398例患者接受清髓性异体HSCT;195例患者接受非清髓性/降低强度的异体HSCT;969例患者接受清髓性自体HSCT。清髓性异体方案队列100天时的医疗总费用中位数为289,283美元,非清髓性/降低强度的异体方案队列为253,467美元,清髓性自体方案队列为140,792美元。清髓性异体方案队列中初次(首次理赔)HSCT的平均住院时间为35.6天,非清髓性/降低强度的异体队列中为26.6天,清髓性自体方案队列中为21.8天。
无论使用何种方案,异体HSCT比自体HSCT更昂贵。在异体HSCT队列中,清髓性预处理方案导致的总体成本高于非清髓性/降低强度的方案,这表明高强度预处理方案的住院服务成本负担更大。儿科患者的费用高于成人患者。未来的研究应涉及使用临床数据验证识别预处理方案的算法。